Galvanize Therapeutics Reports Positive Results in Lung Cancer Study
Patients with nonsmall-cell lung cancer (NSCLC) treated with Galvanize Therapeutics’ Aliya pulsed electric field (PEF) system showed more immune response than the non-treated control group, according to initial results from an ongoing trial presented at the Society for Immunotherapy of Cancer's annual meeting in Boston, Nov. 8-12.
The trial is studying adult patients with suspected or confirmed NSCLC who are surgical candidates and have not received treatment for the most extensive tumor in the last two years. It is designed to evaluate the safety and feasibility of the Aliya System for ablation of solid tumors using PEF energy.
PEF-treated patients had tertiary lymphoid structures (TLS) — aggregates of immune cells — observed within the tumors after treatment, indicating an immune system response. No TLS were identified by biopsy before the treatment.
The expected completion date for the 40-participant study is August 2023.